Neurodegenerative Disease Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 55.12 Billion |
| Market Size (2029) | USD 77.82 Billion |
| CAGR (2024 - 2029) | 7.14 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Neurodegenerative Disease Market Analysis
The Neurodegenerative Disease Market size is estimated at USD 55.12 billion in 2024, and is expected to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).
The key growth determinants of the market include the increasing number of neurological disorders, growing awareness globally, and a strong lineup of products for treating neurodegenerative diseases. As the global population grows and people live longer on average, more people are experiencing neurological disorders.
According to data from the National Institute of Environmental Health Sciences, as of June 2022, around 6.2 million Americans had Alzheimer's disease. Furthermore, a study published in the Lancet Journal in March 2024 showed that neurological disorders contribute to 3.4 billion disability-adjusted life-years (DALYs) worldwide. This high burden of neurological disorders is anticipated to increase the demand for treatments and effective methods, driving growth in the neurodegenerative disease market.
The market is set to expand due to increasing attention to developing products for neurodegenerative diseases. For instance, in December 2023, Alpha Cognition reported that the US FDA accepted its New Drug Application for ALPHA-1062, intended for treating Mild-to-Moderate Alzheimer's Disease. ALPHA-1062 is a drug that inhibits acetylcholinesterase, with fewer expected side effects on the stomach.
In March 2024, Prilenia Therapeutics BV shared its plan to submit a Marketing Authorization Application (MAA) for pridopidine to the Medicinal Products for Human Use (CHMP) committee under the European Medicines Agency, seeking approval to treat Huntington's disease (HD). This trend of developing products and obtaining regulatory approvals shows a growing effort to address neurodegenerative diseases, driving market growth.
These factors are expected to contribute to the market's growth during the forecast period. However, strict regulatory requirements and the expiration of patents for treatments of neurodegenerative diseases are significant factors that could hinder market growth.
Neurodegenerative Disease Market Trends
Alzheimer's Disease is Expected to Witness Significant Growth Over the Forecast Period
The segment for Alzheimer's disease is projected to maintain a substantial market share throughout the forecast period. Alzheimer's disease is a progressive condition characterized by the degeneration and eventual death of brain cells, making it the leading cause of dementia—a gradual decline in cognitive, behavioral, and social abilities that impairs independent functioning. The prevalence and mortality rates associated with Alzheimer's disease are on the rise globally, leading to an increase in demand for treatments and therapies to address the condition and thereby stimulating market growth.
The prevalence of Alzheimer's disease is escalating worldwide. For instance, according to the 2024 Alzheimer's Disease Facts and Figures report from the Alzheimer's Association, approximately 6.9 million Americans aged 65 and older have Alzheimer's dementia in 2024, with 75% of them being aged 75 or older. Additionally, the report notes that 1 in 9 individuals aged 65 and older is affected by Alzheimer's dementia. This high incidence of Alzheimer's disease is expected to influence market growth positively.
The segment is benefiting from increased research and development endeavors and the introduction of novel products. For instance, as reported in an April 2024 article by the Alzheimer's Association, in 2024, the Alzheimer's disease drug development pipeline comprised 164 clinical trials evaluating 127 drugs. These drugs target various aspects of Alzheimer's disease pathology, including inflammation, neurotransmitter receptors, amyloid, and synaptic plasticity. Similarly, BioXcel Therapeutics intends to launch a pivotal Phase 3 in-care trial in April 2024 to further evaluate BXCL501 (dexmedetomidine sublingual film) for the acute treatment of agitation in Alzheimer's disease dementia patients.
These advancements within the segment are anticipated to drive its growth significantly. Consequently, owing to these factors, the Alzheimer's disease segment is poised to witness a substantial increase in the forthcoming years.
North America is Expected to Dominate the Market Over the Forecast Period
North America is projected to emerge as the leading market for neurodegenerative diseases. Factors attributing to the growth of this market include the rising prevalence of neurological disorders and ongoing research and development efforts by both private and government organizations aimed at developing treatments for such conditions.
As per a study supported by the Parkinson's Foundation in 2022, around one million individuals in the United States had Parkinson's disease (PD); it is projected that this figure will increase to 1.2 million by 2030. Parkinson's disease ranks as the second most prevalent neurodegenerative disorder, following Alzheimer's disease. Similarly, according to the Statistics Canada data published in January 2024, around 750,000 people reported living with Alzheimer's disease in Canada in 2022. This significant burden of Alzheimer's and Parkinson's disease underscores the need for innovative therapeutics to treat the condition, driving growth in the market within the country.
North America is expected to maintain a substantial market share due to the presence of numerous pharmaceutical companies and advancements in the care paradigm for patients with neurodegenerative diseases. For instance, in November 2023, NeureSense Therapeutics Ltd reported the successful conclusion of a Type D meeting with the United States FDA regarding Primes, a treatment for amyotrophic lateral sclerosis (ALS).
In October 2023, US-based CuraSen Therapeutics revealed plans to commence a first-in-human clinical trial with CST-3056, a new drug for neurodegenerative diseases, in April 2024. The biopharmaceutical company recently secured USD 5.8 million in funding from the Alzheimer's Drug Discovery Foundation to support nonclinical safety studies, which was expected to commence in early 2024. The first Phase I clinical trial is expected to happen later in the year.
With numerous activities related to drug development and regulatory approvals, the market is poised to experience significant growth over the forecast period in North America.
Neurodegenerative Disease Industry Overview
The market is semi-consolidated due to the presence of a few major market players. The major players adopt strategic methods such as mergers and acquisitions, partnerships and collaborations, investments in research and development activities, and new product launches to withstand the global competitive rivalry. Some major market players are AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceuticals, Novartis AG, and UCB SA.
Neurodegenerative Disease Market Leaders
-
Boehringer Ingelheim International GmbH
-
UCB SA
-
Novartis AG
-
Teva Pharmaceutical
-
Merck & Co Inc.
*Disclaimer: Major Players sorted in no particular order
Neurodegenerative Disease Market News
- March 2024: Creyon Bio reported a strategic collaboration with Cajal Neuroscience to develop oligonucleotide-based medical solutions targeting various neurodegenerative diseases.
- December 2023: Evotec and BMS entered into a license agreement as part of their Neuroscience Alliance. The agreement covers selected late-stage discovery programs aimed at identifying disease-modifying treatments for neurodegenerative diseases.
Neurodegenerative Disease Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Neurological Disorders
- 4.2.2 Increasing Public Awareness
- 4.2.3 Strong Product Pipeline for Neurodegenerative Disease Treatment
-
4.3 Market Restraints
- 4.3.1 Patent Expiry of Neurodegenerative Disease Treatment Products
- 4.3.2 Stringent Regulatory Guidelines
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Indication Type
- 5.1.1 Parkinson's Disease
- 5.1.2 Alzheimer's Disease
- 5.1.3 Multiple Sclerosis
- 5.1.4 Huntington Disease
- 5.1.5 Other Indication Types
-
5.2 By Drug Type
- 5.2.1 N-methyl-D-aspartate Receptor Antagonists
- 5.2.2 Cholinesterase Inhibitors
- 5.2.3 Dopamine Agonists
- 5.2.4 Immunomodulatory Drugs
- 5.2.5 Other Drug Types
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 Amneal Pharmaceuticals Inc.
- 6.1.3 Boehringer Ingelheim International GmbH
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 Merck & Co. Inc.
- 6.1.6 Novartis AG
- 6.1.7 Pfizer Inc.
- 6.1.8 Teva Pharmaceutical Industries Ltd
- 6.1.9 UCB S.A.
- 6.1.10 Biogen Inc.
- 6.1.11 Johnson & Johnson Services Inc.
- 6.1.12 Sanofi
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNeurodegenerative Disease Industry Segmentation
As per the scope of the report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and neuron degradation leads to neurons' gradual death.
The market is segmented by indication type, drug type, and geography. By indication type, the market is segmented into Parkinson's disease, Alzheimer's Disease, multiple sclerosis, Huntington's disease, and other indication types. By drug type, the market is segmented into N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors, dopamine agonists, immunomodulatory drugs, and other drug types. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the market sizes and forecasts in 17 countries across the major regions. For each segment, the market size is provided in terms of value (USD).
| By Indication Type | Parkinson's Disease | |
| Alzheimer's Disease | ||
| Multiple Sclerosis | ||
| Huntington Disease | ||
| Other Indication Types | ||
| By Drug Type | N-methyl-D-aspartate Receptor Antagonists | |
| Cholinesterase Inhibitors | ||
| Dopamine Agonists | ||
| Immunomodulatory Drugs | ||
| Other Drug Types | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Neurodegenerative Disease Market Research FAQs
How big is the Neurodegenerative Disease Market?
The Neurodegenerative Disease Market size is expected to reach USD 55.12 billion in 2024 and grow at a CAGR of 7.14% to reach USD 77.82 billion by 2029.
What is the current Neurodegenerative Disease Market size?
In 2024, the Neurodegenerative Disease Market size is expected to reach USD 55.12 billion.
Who are the key players in Neurodegenerative Disease Market?
Boehringer Ingelheim International GmbH, UCB SA, Novartis AG, Teva Pharmaceutical and Merck & Co Inc. are the major companies operating in the Neurodegenerative Disease Market.
Which is the fastest growing region in Neurodegenerative Disease Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Neurodegenerative Disease Market?
In 2024, the North America accounts for the largest market share in Neurodegenerative Disease Market.
What years does this Neurodegenerative Disease Market cover, and what was the market size in 2023?
In 2023, the Neurodegenerative Disease Market size was estimated at USD 51.18 billion. The report covers the Neurodegenerative Disease Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Neurodegenerative Disease Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Neurodegenerative Diseases Industry Report
The Global Neurodegenerative Disease Market Report provides an in-depth industry analysis, covering various indication types such as Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington's Disease, and other indication types. The report also segments the market by drug types, including N-Methyl-D-Aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, and other drug types. The market research offers a comprehensive industry overview, highlighting the market size and market segmentation across different geographical regions, including North America, Europe, Asia-Pacific, The Middle East and Africa, and South America.
The market forecast and market predictions are based on detailed market data and industry statistics, ensuring a thorough understanding of the market value and market growth. The report example and report pdf provide a clear market outlook and industry outlook, offering insights into market trends and industry trends. The market review also includes an analysis of market leaders and their impact on market growth.
The industry reports and industry research delve into the growth rate and industry sales, providing a detailed industry size and market overview. The report highlights the importance of market leaders and their role in driving market growth. The industry information and research analysis are crucial for understanding the market dynamics and market forecast.
Overall, this market report is an essential resource for research companies and professionals seeking a comprehensive understanding of the neurodegenerative disease market. The report's market analysis and industry trends offer valuable insights into market predictions and market value, making it a vital tool for strategic planning and decision-making.
